|1.||McDonnell, Donald P: 2 articles (10/2007 - 05/2005)|
|2.||Jordan, V Craig: 2 articles (01/2006 - 06/2002)|
|3.||Chen, John J: 1 article (10/2010)|
|4.||Kim, Hyo Jeong: 1 article (10/2010)|
|5.||Okamoto, Kanako: 1 article (10/2010)|
|6.||Laxmi, Y R Santosh: 1 article (10/2010)|
|7.||Kim, Sung Yeon: 1 article (10/2010)|
|8.||Liu, Xiaoping: 1 article (10/2010)|
|9.||Okamoto, Yoshinori: 1 article (10/2010)|
|10.||Suzuki, Naomi: 1 article (10/2010)|
|1.||Breast Neoplasms (Breast Cancer)
06/01/2002 - "Therefore, based on our findings, GW5638 could be developed as a second line agent for advanced breast cancer patients and an important first line agent to evaluate as an adjuvant treatment or chemopreventive."
05/13/2005 - "This dual mechanism of antagonism may explain why GW5638 can inhibit tamoxifen-resistant breast tumors."
06/01/2002 - "GW5638 and ICI182,780 but not raloxifene were also effective in blocking the tamoxifen-stimulated breast tumor growth in athymic mice. "
06/01/2002 - "More importantly, GW5638, like the pure antiestrogen ICI182,780, is able to block the growth of breast cancer stimulated by tamoxifen differently from raloxifene. "
05/10/2002 - "Comparison of the effects of EM-652 (SCH57068), tamoxifen, toremifene, droloxifene, idoxifene, GW-5638 and raloxifene on the growth of human ZR-75-1 breast tumors in nude mice."
06/01/2002 - "GW5638 did not promote tumor growth, and was effective in blocking the effects of postmenopausal estradiol on the growth of tamoxifen-naïve breast and endometrial tumors. "
10/01/2007 - "Contained within this class of molecules is the steroidal antiestrogen ICI182,780 (faslodex), recently approved for the treatment of metastatic cancer, and GW5638/DPC974, a SERD that is currently being evaluated in the clinic. "
|3.||Endometrial Neoplasms (Endometrial Cancer)
06/01/2002 - "The purpose was to evaluate the effects of the new tamoxifen analogue GW5638 on breast and endometrial cancer growth. "
06/01/2002 - "Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo."
06/01/2002 - "GW5638 is more effective than raloxifene in blocking the effect of estrogen on tamoxifen-naïve endometrial cancer. "
|5.||Estrogen Receptor Modulators (Antiestrogen)
|9.||Selective Estrogen Receptor Modulators (SERM)